Last reviewed · How we verify
Levocetirizine tablets
Selective histamine H1 receptor antagonist
Selective histamine H1 receptor antagonist Used for Allergic rhinitis, Chronic urticaria.
At a glance
| Generic name | Levocetirizine tablets |
|---|---|
| Also known as | Xyzal |
| Sponsor | UCB Pharma |
| Drug class | Antihistamine |
| Target | Histamine H1 receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 2 |
Mechanism of action
Levocetirizine is a non-sedative, second-generation antihistamine that selectively inhibits peripheral H1-receptors without significant anticholinergic or central nervous system side effects.
Approved indications
- Allergic rhinitis
- Chronic urticaria
Common side effects
- Drowsiness
- Headache
- Fatigue
- Dry mouth
- Nausea
Key clinical trials
- Parallel, Double-dummy, Superiority Study Levocetirizine/Pseudoephedrine x Zina for Allergic Rhinitis in Brazil (PHASE3)
- COrticosteroids in acUte uRticAria in emerGency dEpartment (PHASE3)
- Treatment Options for Chronic Urticaria (PHASE2)
- ATAREAL (Antihistamine Treatment for Allergic Rhinitis in Real Life) (PHASE4)
- The Duration of the Suppressive Effects of Desloratadine on Allergen Prick Tests After Discontinuation (P04441) (PHASE4)
- A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis (PHASE4)
- Bioequivalence Study Between Levocetirizine Oral Disintegrating Tablet (ODT) and Levocetirizine Immediate Release Tablet (IRT) (PHASE1)
- Influence of H1-antihistamines on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Levocetirizine tablets CI brief — competitive landscape report
- Levocetirizine tablets updates RSS · CI watch RSS
- UCB Pharma portfolio CI